hearing MIDD Syndrome

Hearing loss in MIDD often affects both ears and may change over time. High-pitched sounds can be affected early, but the pattern is not identical for everyone. Hearing tests help establish what is affected and how much support would be useful for everyday communication. Hearing loss is commonly bilateral, progressive and sensorineural. High-frequency involvement is frequent, but audiometric patterns vary; assessment should consider both thresholds and functional communication needs. ^{[4, 9, 10, 11]}

The inner ear needs energy to turn sound into signals, and mitochondrial dysfunction can interfere with that process. Care is based on your hearing and communication needs, rather than waiting for a particular degree of difficulty before discussing help. Cochlear energy dysfunction contributes to mitochondrial sensorineural hearing loss. Support should reflect audiological findings and communication needs. ^{[4, 9, 10, 11]}

Management

• Hearing checks: agree a repeat testing schedule with audiology, and report changes between visits. Audiology: obtain baseline and serial assessment; consensus suggests yearly to two-yearly testing, adapted to clinical need. ^{[4, 11]}
• Hearing aids: discuss fitting and adjustments when hearing loss affects communication. Amplification: hearing aid fitting should reflect audiometry, speech understanding and functional communication needs. ^{[4, 11]}
• Cochlear implants: an implant assessment may help if hearing aids no longer provide enough benefit. Small m.3243A>G studies report useful outcomes, but results vary. Cochlear implantation: consider specialist assessment for severe hearing loss with inadequate hearing-aid benefit. Small m.3243A>G series support potential benefit; auditory, cognitive and rehabilitation factors influence outcomes. ^{[4, 11]}
• Communication support: ask about captions, assistive listening equipment and changes at school or work. Communication support: assistive technology, speech support and educational or workplace adjustments can be considered alongside amplification. ^{[4, 11]}

MIDD can reduce the insulin your pancreas makes, and your body may also respond less well to insulin. These changes can affect blood sugar in different ways, so treatment is based on your results and overall health. It is a genetic form of diabetes, and what you need may change over time. Mitochondrial dysfunction can impair beta-cell insulin secretion, while insulin resistance may also contribute. Treatment should reflect residual secretion, glycaemic status and comorbidities, with reassessment over time. ^{[1, 5]}

These are typical patterns, not a way to diagnose diabetes yourself. Features can overlap.

Treatment

Insulin is needed when your body cannot make enough or your glucose levels require it. There is no fixed number of years before everyone with MIDD needs insulin, so your own results matter more than a general timeline. Insulin is indicated according to insulin deficiency and glycaemic status. Time to insulin requirement varies substantially and should not be inferred from a fixed disease duration. ^{[1, 5]}

• Sulfonylureas or glinides: these can help some people who still make insulin. Your team will discuss low blood sugar risk. Insulin secretagogues: may be useful with residual beta-cell function; hypoglycaemia risk needs assessment. ^{[1, 5]}
• Other diabetes medicines: your team may consider options such as DPP-4, GLP-1 or SGLT2 medicines. Evidence specifically in MIDD is limited, and weight, digestion and other risks matter. Other agents: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors have been proposed, largely using extrapolated evidence. Weight loss, gastrointestinal tolerance and ketoacidosis risk require individual assessment. ^{[1, 5]}

Food advice and treatment need to work together, particularly if appetite or digestion makes eating difficult. Make a plan with your diabetes team and dietitian for everyday meals and for days when you are unwell or eating less. The nutrition guide covers practical adjustments. Coordinate nutritional adequacy, carbohydrate intake and sick-day management with medication, insulin reserve and gastrointestinal involvement. See the nutrition guide. ^{[1, 5, 12]}

No single diabetes medicine is best for everyone with MIDD. Make changes with your prescribing team, especially during illness or when eating less. No MIDD-specific randomised trials establish a universal treatment sequence. Reassess medication with changes in organ function, nutritional status or intercurrent illness. ^{[1, 4, 5]}

MIDD can cause changes in the macula, the part of the retina used for detailed central vision. An eye examination may pick these up before you notice a change in sight. These mitochondrial changes are a reason for eye follow-up alongside checks for diabetes-related eye disease. MIDD-associated macular pattern dystrophy may be detected despite relatively preserved visual acuity. Ophthalmic surveillance should assess mitochondrial maculopathy as well as diabetic retinopathy. ^{[4, 13]}

Care: arrange eye checks with your team. These can assess both mitochondrial retinal changes and diabetes-related eye disease. Care: ophthalmic surveillance should assess mitochondrial maculopathy and other pathology, including diabetic retinopathy; follow-up depends on findings. ^{[4, 13]}

Mitochondrial disease can affect the heart muscle or the electrical system that controls its rhythm. Someone may need checks even if they have not noticed heart symptoms. Your history and test results help the team decide what follow-up is appropriate. Cardiomyopathy and conduction or rhythm abnormalities can occur without symptoms that reflect the full degree of involvement. Individualise assessment and surveillance to cardiac history and findings. ^[4]

Care: discuss a heart tracing and heart ultrasound, with repeat tests based on your results. Heart symptoms need assessment between routine visits. Care: baseline ECG and echocardiography, with ongoing ECG surveillance and other investigations individualised to cardiac findings and symptoms. ^[4]

Kidney involvement can affect the filters or the small tubes that help control water and minerals. Protein in the urine can be one clue, which is why urine tests may be part of follow-up as well as blood tests. The team will interpret these findings alongside blood pressure and your other health needs. Renal involvement can include glomerular disease and tubular dysfunction. Proteinuria may be a presenting feature; interpret blood and urine findings alongside blood pressure and the wider clinical picture. ^{[4, 14]}

Care: your plan may include blood pressure, blood and urine checks. Abnormal results may need a kidney specialist. Care: assess blood pressure, renal function, electrolytes and urine abnormalities, with nephrology input when indicated. ^{[4, 14]}

• Digestion: constipation, slow stomach emptying and swallowing difficulties can affect eating. Severe pain, swelling or persistent vomiting needs urgent assessment. Gastrointestinal involvement: dysmotility and dysphagia can compromise nutrition. Acute obstructive symptoms require urgent evaluation. ^[12]
• Muscles: weakness and low exercise tolerance can occur, with a wide range of severity. Myopathy: muscle weakness and exercise intolerance may occur with variable severity. ^{[7, 8]}
• Headaches: migraines can occur. A new or unusual headache, especially with neurological changes, should not simply be assumed to be your usual migraine. Migraine: migraine-like headache is reported in m.3243A>G disease; a new neurological presentation requires differential diagnosis. ^{[7, 8]}
• Mood and thinking: fatigue, anxiety, low mood or thinking difficulties can affect daily life. These are worth discussing with your team. Neuropsychological features: fatigue, mood symptoms and cognitive difficulties warrant assessment; measured heteroplasmy alone does not determine them. ^{[7, 8, 15]}
• Neurological changes: some people also develop stroke-like episodes. Seek emergency help for new weakness, speech or vision changes, confusion or seizures. Phenotypic overlap: m.3243A>G can also cause stroke-like episodes. New focal deficits, encephalopathy or seizures require urgent assessment. ^{[4, 16]}

Keep an up-to-date medicine list and an emergency plan agreed with your team. Drug risks depend on the exact diagnosis and your health. Read the medication guide. Review drugs in the context of genotype, organ involvement, indication and duration. Use an individual emergency plan. Medication guide. ^{[2, 3]}

• Metformin: ask for an individual review; guidance differs and acid buildup risk matters. Metformin: reconcile older avoidance guidance with newer conditional use proposals using individual lactic acidosis risk. ^{[4, 5]}
• Aminoglycosides: review hearing, kidney and genetic risks before use. Aminoglycosides: assess ototoxicity, nephrotoxicity and MT-RNR1 genotype-specific risk. ^{[2, 4]}
• Valproate: it must not be used in POLG-related mitochondrial disease. In other mitochondrial conditions, specialists may consider it for seizures or mood disorders that have not responded to other treatments, only when there is no liver impairment and other safety requirements are met. Pregnancy and reproductive risks need a separate review. Do not stop prescribed treatment yourself. Valproate: contraindicated in POLG-related disease. The 2024 consensus allows consideration for refractory epilepsy or refractory mood disorders in non-POLG mitochondrial disease without liver impairment, subject to other contraindications and reproductive safety requirements. Specialist supervision is essential; avoid unsupervised withdrawal. ^{[3, 17]}
• Linezolid: may be needed for some infections; your team may monitor for acid buildup. Linezolid: review indication and duration, with lactate monitoring where appropriate. ^[2]
• Other antibiotics: tell the prescriber your diagnosis and medicine list so risks and alternatives can be checked. Other antibiotics: assess indication, mitochondrial toxicity evidence, organ function and available alternatives. ^{[2, 3]}
• Propofol: a brief anaesthetic dose is different from a long infusion. Ask the anaesthetist to plan for your mitochondrial condition. Propofol: prolonged infusion carries distinct risk from brief induction; perioperative management requires individual assessment. ^{[2, 4]}

Supplements are sometimes used, but most have limited evidence that they change the course of m.3243A>G disease. The purpose of each product should be clear, including what benefit is being looked for and when it will be reviewed. The supplements guide brings the evidence together. Routine supplement combinations lack robust disease-modifying evidence in m.3243A>G. Define each indication, intended outcome and review plan. See the supplements guide. ^{[16, 18, 19, 20]}

CoQ10 has limited trial evidence; it is not proven to stop MIDD progression. Small mixed-disease trials show limited effects; MIDD disease modification is unproven. ^[20]